Evidence map›Paper›PMID 36721367›Full record

ArticleBiophysical journal2023

Allosteric modulation of α1β3γ2 GABA

Jeevan B Gc, Christopher T Szlenk, Ayobami Diyaolu, Peter Obi, Haiyang Wei, Xutong Shi, K Michael Gibson, Senthil Natesan, Jean-Baptiste Roullet

Open access · bronzeAbstract read
In one paragraph

Article in Biophysical journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jeevan B GcCollege of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington.
Christopher T SzlenkCollege of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington.
Ayobami DiyaoluCollege of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington.
Peter ObiCollege of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington.
Haiyang WeiEurofins Panlabs, Inc., St. Charles, Missouri.
Xutong ShiCollege of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington.
K Michael GibsonCollege of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington.
Senthil NatesanCollege of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington. Electronic address: senthil.natesan@wsu.edu.
Jean-Baptiste RoulletCollege of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington. Electronic address: j.roullet@wsu.edu.
Washington State University Spokane · US

Funding

Natural History of Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD), a Heritable Disorder of GABA MetabolismR01HD091142 · NICHD · WASHINGTON STATE UNIVERSITY · PI Phillip Lawrence Pearl · 2018 to 2026
$5.3M
Rapalog Therapy in Heritable and Vigabatrin-Induced GABA Metabolic DisordersR01EY027476 · NEI · WASHINGTON STATE UNIVERSITY · PI GIBSON, K MICHAEL · 2017 to 2020
$1.7M
Molecular biophysics of integrin activation by oxysterols and rational discovery of small-molecule modulatorsR01GM137022 · NIGMS · WASHINGTON STATE UNIVERSITY · PI NATESAN, SENTHIL KUMAR · 2020 to 2023
$1.2M
Specifics of "Non-Specific Membrane Interactions" of Drugs: An Integrated Approach for Understanding Structure-Membrane Interaction RelationshipsR15GM131293 · NIGMS · WASHINGTON STATE UNIVERSITY · PI NATESAN, SENTHIL KUMAR · 2018 to 2018
$458k
Farnesol as Novel Treatment in Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD)R41NS107057 · NINDS · SPERAGEN, INC. · PI GIBSON, K MICHAEL, MCCONNELL, ALICE · 2018 to 2018
$223k
NEI NIH HHS R01 EY027476NICHD NIH HHS R01 HD091142NIGMS NIH HHS R01 GM137022NIGMS NIH HHS R15 GM131293NINDS NIH HHS R41 NS107057
6 · The paper itself

Abstract

In mammalian cells, all-trans farnesol, a 15-carbon isoprenol, is a product of the mevalonate pathway. It is the natural substrate of alcohol dehydrogenase and a substrate for CYP2E1, two enzymes implicated in ethanol metabolism. Studies have shown that farnesol is present in the human brain and inhibits voltage-gated Ca

Indexed as

NeurosteroidsReceptors, GABA-ABinding SitesFarnesolgamma-Aminobutyric AcidHumansProtein DomainsFarnesolgamma-Aminobutyric AcidNeurosteroidsReceptors, GABA-A

Identifiers

PMID36721367
PMCPMC10027449
OpenAlexW4318567265

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.